Motilal Oswal has kept a Neutral rating on Alkyl Amines Chemicals with a price target of Rs 1,950. While the company reported a strong 74% jump in operating profit for Q1 FY27, the brokerage remains cautious due to current valuations. Investors should track demand trends in the pharma and agrochemical sectors and monitor potential risks from import competition.
Motilal Oswal Securities has maintained a 'Neutral' rating on Alkyl Amines Chemicals (AACL), assigning a target price of Rs 1,950 per share. This view follows the company’s financial performance for the first quarter of the 2027 fiscal year, which showed notable growth in both revenue and profitability.
During Q1 FY27, the company reported a revenue of Rs 528 crore, marking a 30.2% increase compared to the previous year. Profit after tax (PAT) saw a significant rise of approximately 91%, reaching Rs 95 crore. A primary factor behind these numbers was the operating profit (EBITDA), which surged by 74% to Rs 133 crore. The company improved its operating profit margin to 25.3%, a gain of 640 basis points, largely achieved by effectively passing on raw material cost increases to its customers and benefiting from improved operating leverage.
Looking ahead, the brokerage has revised its earnings estimates for FY27 and FY28 upwards by 28% and 17%, respectively. Analysts expect the company to benefit from steady demand in the pharmaceutical sector—particularly for peptide-based products—alongside consistent requirements from the agrochemical and rubber chemical industries. The company’s strategic shift toward launching new product categories and expanding market share is also viewed as a potential driver for future growth.
Despite the strong operational numbers, the 'Neutral' rating indicates that the current market price of Rs 1,921.20 is already close to the brokerage's target. This suggests that the stock's valuation, calculated at 40 times the estimated earnings per share for FY28, may already account for the expected growth momentum.
Investors should keep in mind that the specialty chemicals industry can be cyclical and sensitive to global demand shifts. The company also faces ongoing challenges, such as pressure from low-cost imports and the need to manage price volatility in raw materials like ammonia and methanol. Furthermore, the company’s ability to successfully execute its plans for new product commercialization and maintain high capacity utilization will be critical. The market will likely look for updates on how these factors evolve in the upcoming quarters.